"Sitagliptin Phosphate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrazine-derived DIPEPTIDYL-PEPTIDASE IV INHIBITOR and HYPOGLYCEMIC AGENT that increases the levels of the INCRETIN hormones GLUCAGON-LIKE PEPTIDE-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). It is used in the treatment of TYPE 2 DIABETES.
| Descriptor ID |
D000068900
|
| MeSH Number(s) |
D03.383.129.799.725 D03.383.679.875
|
| Concept/Terms |
Sitagliptin Phosphate- Sitagliptin Phosphate
- Phosphate, Sitagliptin
- Sitagliptin Phosphate Monohydrate
- Monohydrate, Sitagliptin Phosphate
- Phosphate Monohydrate, Sitagliptin
- Sitagliptin Monophosphate Monohydrate
- Monohydrate, Sitagliptin Monophosphate
- Monophosphate Monohydrate, Sitagliptin
MK 0431- MK 0431
- 0431, MK
- MK0431
- MK-0431
Sitagliptin- Sitagliptin
- 4-Oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine
|
Below are MeSH descriptors whose meaning is more general than "Sitagliptin Phosphate".
Below are MeSH descriptors whose meaning is more specific than "Sitagliptin Phosphate".
This graph shows the total number of publications written about "Sitagliptin Phosphate" by people in this website by year, and whether "Sitagliptin Phosphate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 1 | 2 |
| 2017 | 2 | 3 | 5 |
| 2018 | 5 | 4 | 9 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Sitagliptin Phosphate" by people in Profiles.
-
Sitagliptin: a potential drug for the treatment of COVID-19? Acta Pharm. 2021 Jun 01; 71(2):175-184.
-
Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease. ChemMedChem. 2021 05 06; 16(9):1425-1426.
-
Reduced COVID-19 Mortality With Sitagliptin Treatment? Weighing the Dissemination of Potentially Lifesaving Findings Against the Assurance of High Scientific Standards. Diabetes Care. 2020 12; 43(12):2906-2909.
-
Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy. Diabetes Care. 2020 12; 43(12):3042-3049.
-
Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study. Diabetes Care. 2020 12; 43(12):2999-3006.
-
Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era? J Diabetes Complications. 2020 12; 34(12):107723.
-
Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin. Med Hypotheses. 2020 Oct; 143:110111.
-
Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung. Iran J Allergy Asthma Immunol. 2020 May 17; 19(S1):10-12.
-
Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Hepatology. 2019 06; 69(6):2414-2426.
-
Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth. Nat Immunol. 2019 03; 20(3):257-264.